NCT03193125

Carnitine and Liver Mitochondria Fatty Acid Processing

Effects of Carnitine Supplementation on Liver Mitochondria Fatty Acid Processing

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Pennington Biomedical Research Center · Academic / Other
• Sex: All
• Age: 20 Years – 40 Years
• Healthy volunteers: Accepted

Summary

This double-blind, placebo-controlled randomized trial will assess whether 14 days of oral carnitine supplementation modifies mitochondrial fatty acid processing in healthy young adults.

Detailed description

This project will use stable isotope techniques and magnetic resonance spectroscopy (MRS) to take a first step toward clarifying how the benefit of oral carnitine supplementation depends on basal mitochondrial fatty acid processing (MFAP) and MFAP modification, with a specific focus on the liver. Approximately 24 healthy young individuals will be enrolled, with 20 expected to complete. Before and after 14 days of oral carnitine supplementation or placebo, MFAP will be measured using measures of acetyl-carnitine concentration (from long-TE proton MRS) and de novo lipogenesis (DNL, from analysis of blood metabolites following 13C-labeled acetate infusion and high-fructose drink challenge). The MFAP measures will be collected before and after loading participants with a high-fructose drink. Fructose is solely metabolized by the liver.

Conditions

• Diabetes Mellitus, Type 2
• Insulin Resistance
• Obesity

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	L-Carnitine	500 mg tablets of L-Carnitine taken 3 times daily before meals.
DIETARY_SUPPLEMENT	Placebo	500 mg tablets of L-Carnitine taken 3 times daily before meals.

Timeline

• Start date: 2017-05-15
• Primary completion: 2018-05-11
• Completion: 2018-05-11
• First posted: 2017-06-20
• Last updated: 2022-09-29

Locations

1 site across 1 country: United States